MedTrace Logo

GILT Docetaxel - Non-Small Cell Lung Cancer

NCT00174629 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 449

Last updated 2009-12-07

No results posted yet for this study

Summary

Primary Objective:

* To compare response rate between genotypic groups and control group.

Secondary Objective:

* To determine the safety, time to treatment failure and survival in control and genotypic arms.

Conditions

  • Lung Neoplasms

Interventions

DRUG

Docetaxel/DDP

DRUG

docetaxel/gemcitabine

Sponsors & Collaborators

Principal Investigators

  • Jean-Philippe Aussel · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-06-30
Primary Completion
2007-01-31

Countries

  • Germany
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00174629 on ClinicalTrials.gov